News coverage about Zai Lab (NASDAQ:ZLAB) has trended somewhat positive on Wednesday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zai Lab earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.6455397568238 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
Shares of NASDAQ ZLAB traded down $0.28 during midday trading on Wednesday, reaching $23.25. 17,270 shares of the company were exchanged, compared to its average volume of 67,973. The firm has a market cap of $1.19 billion and a P/E ratio of -10.02. Zai Lab has a 1 year low of $17.85 and a 1 year high of $35.74.
ZLAB has been the topic of a number of research reports. BidaskClub raised Zai Lab from a “hold” rating to a “buy” rating in a report on Wednesday, April 11th. Zacks Investment Research raised Zai Lab from a “sell” rating to a “hold” rating in a report on Thursday, June 7th. ValuEngine raised Zai Lab from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, Leerink Swann reissued an “outperform” rating on shares of Zai Lab in a report on Friday, March 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $37.50.
About Zai Lab
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.